Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Panacea Biotec's operating assets for the quarter that ended in Jun. 2026 was ₹0 Mil. Panacea Biotec's operating liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil. Panacea Biotec's Total Assets for the quarter that ended in Mar. 2026 was ₹12,622 Mil. Therefore, Panacea Biotec's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.00.
Panacea Biotec Scaled Net Operating Assets Related Terms
Panacea Biotec Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, MRNA: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Panacea Biotec's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.00 mean?
Panacea Biotec (BOM:531349) has a Scaled Net Operating Assets of 0.00 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Panacea Biotec and its competitors.
Is Panacea Biotec's Scaled Net Operating Assets too high?
Panacea Biotec's current Scaled Net Operating Assets is 0.00. Overall, Panacea Biotec has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Scaled Net Operating Assets compare to VRTX and REGN?
Panacea Biotec's Scaled Net Operating Assets of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current Scaled Net Operating Assets is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹405.09, compared to a current price of ₹389.35 — trading 3.9% below its estimated fair value. The current Scaled Net Operating Assets is 0.00. Panacea Biotec's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Scaled Net Operating Assets is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued.
The current stock price of ₹389.35 is trading 3.9% below its estimated GF Value™ of ₹405.09.
GuruFocus considers Panacea Biotec to be Fairly Valued.
Key valuation signals for BOM:531349:
Scaled Net Operating Assets: 0.00
GF Value™: ₹405.09 vs. price of ₹389.35 (3.9% below fair value)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
60GF Score
Get the complete analysis for BOM:531349
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
